Skip to main content

Table 1 Subgroup analysis according to region, study design and NOS score

From: Cholelithiasis and the risk of intrahepatic cholangiocarcinoma: a meta-analysis of observational studies

   

Heterogeneity

Confounding factors

NO. studies

Odds ratio (95 % CI)

I 2

p

Region

 Eastern

    

  BDST

4

12.34 (4.54–33.57)

59.1 %

0.062

  GBST

4

1.77 (0.88–3.58)

85.7 %

0.000

 Western

    

  BDST

2

23.35 (17.63–30.92)

0.0 %

0.974

  GBST

2

2.81 (1.03–7.72)

36.3 %

0.210

Study design

 Nationwide

    

  BDST

3

21.07 (16.85–26.36)

0.0 %

0.494

  GBST

2

2.78 (2.37–3.26)

0.0 %

0.328

 Hospital-based

    

  BDST

3

9.75 (1.73–54.84)

62.5 %

0.056

  GBST

4

1.42 (0.63–3.19)

70 %

0.019

NOS score

 High

    

  BDST

3

18.49 (12.90–26.50)

0.0 %

0.463

  GBST

3

2.58 (1.59–4.21)

53.2 %

0.118

 Moderate

    

  BDST

3

9.53 (2.55–35.59)

75.2 %

0.018

  GBST

3

1.57 (0.54–4.61)

79.4 %

0.008

  1. CI confidence interval, EHST extrahepatic bile duct stone or choledocholithiasis, GBST gallbladder stone or cholecystolithiasis
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us